These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 33852479)
1. Spironolactone and Eplerenone Use at Discharge in Heart Failure Patients With Reduced Ejection Fraction at 3 Large Hospital Systems. Jacobs D; Moreno V; Rubio A; Moote R; Lipscomb J; Davis H; Allen S; Oliver A Am J Ther; 2023 May; 30(3):e282-e284. PubMed ID: 33852479 [No Abstract] [Full Text] [Related]
2. Real world comparison of spironolactone and eplerenone in patients with heart failure. Pardo-Martínez P; Barge-Caballero E; Bouzas-Mosquera A; Barge-Caballero G; Couto-Mallón D; Paniagua-Martín MJ; Sagastagoitia-Fornie M; Prada-Delgado Ó; Muñiz J; Almenar-Bonet L; Vázquez-Rodríguez JM; Crespo-Leiro MG Eur J Intern Med; 2022 Mar; 97():86-94. PubMed ID: 35000806 [TBL] [Abstract][Full Text] [Related]
3. Mineralocorticoid receptor antagonists in heart failure with preserved ejection fraction (HFpEF). Capuano A; Scavone C; Vitale C; Sportiello L; Rossi F; Rosano GM; Coats AJ Int J Cardiol; 2015 Dec; 200():15-9. PubMed ID: 26404747 [TBL] [Abstract][Full Text] [Related]
4. Comparison of effects of aldosterone receptor antagonists spironolactone and eplerenone on cardiovascular outcomes and safety in patients with acute decompensated heart failure. Yamamoto M; Seo Y; Ishizu T; Nishi I; Hamada-Harimura Y; Machino-Ohtsuka T; Higuchi H; Sai S; Nakatsukasa T; Sugano A; Baba M; Obara K; Aonuma K Heart Vessels; 2019 Feb; 34(2):279-289. PubMed ID: 30203391 [TBL] [Abstract][Full Text] [Related]
5. [Role of eplerenone in the threatment of cardiovascular diseases]. Málek F Vnitr Lek; 2023; 69(E-2):23-25. PubMed ID: 37072263 [TBL] [Abstract][Full Text] [Related]
6. Mineralocorticoid Receptor Antagonists, Blood Pressure, and Outcomes in Heart Failure With Reduced Ejection Fraction. Serenelli M; Jackson A; Dewan P; Jhund PS; Petrie MC; Rossignol P; Campo G; Pitt B; Zannad F; Ferreira JP; McMurray JJV JACC Heart Fail; 2020 Mar; 8(3):188-198. PubMed ID: 31926854 [TBL] [Abstract][Full Text] [Related]
7. Effects of long-term monotherapy with eplerenone, a novel aldosterone blocker, on progression of left ventricular dysfunction and remodeling in dogs with heart failure. Suzuki G; Morita H; Mishima T; Sharov VG; Todor A; Tanhehco EJ; Rudolph AE; McMahon EG; Goldstein S; Sabbah HN Circulation; 2002 Dec; 106(23):2967-72. PubMed ID: 12460880 [TBL] [Abstract][Full Text] [Related]
9. Randomized, double-blind, multicenter, placebo-controlled study evaluating the effect of aldosterone antagonism with eplerenone on ventricular remodeling in patients with mild-to-moderate heart failure and left ventricular systolic dysfunction. Udelson JE; Feldman AM; Greenberg B; Pitt B; Mukherjee R; Solomon HA; Konstam MA Circ Heart Fail; 2010 May; 3(3):347-53. PubMed ID: 20299607 [TBL] [Abstract][Full Text] [Related]
10. Eplerenone, an aldosterone antagonist, reduces hospitalization and death in heart failure patients with NYHA class II and an ejection fraction of less than 30%. Birocchi S; Cernuschi GC; Intern Emerg Med; 2011 Oct; 6(5):453-4. PubMed ID: 21769601 [No Abstract] [Full Text] [Related]
11. Data-Driven Approach to Identify Subgroups of Heart Failure With Reduced Ejection Fraction Patients With Different Prognoses and Aldosterone Antagonist Response Patterns. Ferreira JP; Duarte K; McMurray JJV; Pitt B; van Veldhuisen DJ; Vincent J; Ahmad T; Tromp J; Rossignol P; Zannad F Circ Heart Fail; 2018 Jul; 11(7):e004926. PubMed ID: 29997240 [TBL] [Abstract][Full Text] [Related]
12. Steroidal and Novel Non-steroidal Mineralocorticoid Receptor Antagonists in Heart Failure and Cardiorenal Diseases: Comparison at Bench and Bedside. Kolkhof P; Jaisser F; Kim SY; Filippatos G; Nowack C; Pitt B Handb Exp Pharmacol; 2017; 243():271-305. PubMed ID: 27830348 [TBL] [Abstract][Full Text] [Related]
13. Management of heart failure and left ventricular systolic dysfunction following acute myocardial infarction. Conti CR Clin Cardiol; 2005 Jan; 28(1):1-2. PubMed ID: 15704523 [No Abstract] [Full Text] [Related]
14. Update on aldosterone antagonists use in heart failure with reduced left ventricular ejection fraction. Heart Failure Society of America Guidelines Committee. Butler J; Ezekowitz JA; Collins SP; Givertz MM; Teerlink JR; Walsh MN; Albert NM; Westlake Canary CA; Carson PE; Colvin-Adams M; Fang JC; Hernandez AF; Hershberger RE; Katz SD; Rogers JG; Spertus JA; Stevenson WG; Sweitzer NK; Tang WH; Stough WG; Starling RC J Card Fail; 2012 Apr; 18(4):265-81. PubMed ID: 22464767 [TBL] [Abstract][Full Text] [Related]
15. Selection of a mineralocorticoid receptor antagonist for patients with hypertension or heart failure. Iqbal J; Parviz Y; Pitt B; Newell-Price J; Al-Mohammad A; Zannad F Eur J Heart Fail; 2014 Feb; 16(2):143-50. PubMed ID: 24464876 [TBL] [Abstract][Full Text] [Related]
16. Clinical Question: In congestive heart failure patients with preserved ejection fraction, does spironolactone improve cardiac outcomes? Onarecker C J Okla State Med Assoc; 2016 Sep; 109(9):437-8. PubMed ID: 29261854 [TBL] [Abstract][Full Text] [Related]
17. Relative Efficacy of Spironolactone, Eplerenone, and cAnRenone in patients with Chronic Heart failure (RESEARCH): a systematic review and network meta-analysis of randomized controlled trials. Frankenstein L; Seide S; Täger T; Jensen K; Fröhlich H; Clark AL; Seiz M; Katus HA; Nee P; Uhlmann L; Naci H; Atar D Heart Fail Rev; 2020 Mar; 25(2):161-171. PubMed ID: 31364027 [TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of eplerenone in heart failure management. Zheng J; Wang S; Timóteo AT Eur J Intern Med; 2024 May; 123():163-164. PubMed ID: 38365517 [No Abstract] [Full Text] [Related]
19. [The role of aldosterone-antagonists in the treatment of congestive heart failure]. Fügedi K Orv Hetil; 2005 Apr; 146(14):645-8. PubMed ID: 15889538 [TBL] [Abstract][Full Text] [Related]
20. Mineralocorticoid Receptor Antagonists in the Management of Heart Failure and Resistant Hypertension: A Review. Flatt DM; Brown MC; Mizeracki AM; King BJ; Weber KT JAMA Cardiol; 2016 Aug; 1(5):607-12. PubMed ID: 27434136 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]